HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, Volume 2, February 2016 Biomedical Research Governance       » Tissue banking in Singapore — An Evolving Enterprise       » China Recognizes Prominent Scientists and Stresses on Innovation       » NUS Researchers Uncover Potent Parasite-killing Mechanism of Nobel Prize-Winning Anti-Malarial Drug       » A New Water Robot "Born" to Detect Water Quality       » Probing the Mystery of How Cancer Cells Die       » Researchers Find Link between Processed Foods and Autoimmune Diseases       » Unravelling the Genetics of Pregnancy and Heart Failure      
BIOBOARD - US
Positive Signs for Malaria Vaccine Based on GM Parasite

A malaria vaccine based on genetically modified parasites is worth developing further, according to the first study to test the new approach in humans.

Six volunteers were exposed to the malaria parasite Plasmodium falciparum, rendered harmless by genetic modification, through the bite of Anopheles mosquitoes. All six developed antibodies against the parasite without getting infected, reports the proof of concept study.

But at higher doses one volunteer was infected — indicating that the technique for weakening the parasites needs perfecting before further trials can be carried out.

"Our approach is to genetically engineer parasites by deletion of specific genes that are critical for their replication in the liver," Stefan Kappe, a professor at the Seattle Biomedical Research Institute, United States, and one of the authors of the study, says.

"The genetically attenuated parasites can infect the liver, but cannot complete their development and therefore cannot infect the red blood cells. We call this the 'can check in but cannot check out' approach."

Other researchers have tried a similar approach by irradiating the parasites.

"But there is a critical difference," explains Kappe. "While the existing treatment of parasites uses radiation to cause random mutations in the parasite genome, our approach focuses on fully defined gene deletions that can be tweaked to induce optimal immunity. This way we don't rely on chance … but, rather, we design it."

But he says that it is too early to talk about mass implementation of the vaccine. One challenge is figuring out how to produce the weakened parasites in large enough numbers.

"Currently, they can only be made in mosquitoes, but we are working on making them in tissue culture," says Kappe.

Brian Greenwood, professor of clinical tropical medicine at the UK-based London School of Hygiene & Tropical Medicine, believes that the new experimental vaccine "is a valid approach to the development of a human malaria vaccine but it still has a long way to go".

For example, he says, while the study demonstrated that an immune response is triggered by these weakened parasites, it did not then expose volunteers to infectious malaria parasites to show that they would indeed be protected.

There are also safety concerns. "It would be a disaster if a large number of people were immunised with a parasite that had not been weakened sufficiently to prevent it causing clinical malaria in some recipients," says Greenwood.

Kappe says: "Genetic engineering of the parasite is still an art and very cumbersome, but we are getting better at it".

Source: Science Development Network

Click here for the complete issue.

NEWS CRUNCH  
news Singapore Researchers Develop World'S First High-Throughput Imaging Platform for Predicting Kidney Toxicity
news Collaboration is Cure for Better Global Health Outcomes, UK-India Experts Say
news EmTech Asia Opens: Features 50 speakers on innovation and emerging technologies
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Primates in Biomedical Research
COLUMNS  
\
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Cancerology / Oncology
May:
Guest Editorial - Antibody Informatics In Japan
June:
Medical Devices and Technology
July:
Water Technology
August:
Occupational Health
September:
Olympics: Evolution of Sports
October:
Respiratory: Seasonal flu viruses
November:
Tobacco Smoking
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy